CD40LG and infection: Comparing data from the older aged ocrelizumab PPMS trial with data from the ocrelizumab RMS trials, it appears that in the PPMS population the proportion of individuals with IgG and IgM levels below the lower limit of normal is higher, possibly linked with an increase in serious infections in the older population [26].